Baird Financial Group Inc. Decreases Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Baird Financial Group reduced its Thermo Fisher Scientific stake by 18.9% in the second quarter, selling 39,226 shares and retaining 167,777 shares valued at approximately $84.1 million. Institutional investors collectively own 89.23% of the stock.
• Analysts maintain a generally positive outlook, with Thermo Fisher receiving a consensus “Moderate Buy” rating and an average price target of $624.64.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, while revenue increased 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share, yielding approximately 0.3%.

Baird Financial Group Inc. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 167,777 shares of the medical research company's stock after selling 39,226 shares during the quarter. Baird Financial Group Inc.'s holdings in Thermo Fisher Scientific were worth $84,117,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legacy Wealth Managment LLC ID raised its holdings in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. Kilter Group LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $25,000. Allied Private Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $26,000. High Note Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Finally, Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $28,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. CLSA began coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an "outperform" rating and a C$748.00 target price on the stock. Royal Bank Of Canada upped their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a "market perform" rating and a $520.00 target price on the stock. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Finally, Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $624.64.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $607.23 on Thursday. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $647.00. The stock has a market capitalization of $224.52 billion, a price-to-earnings ratio of 32.66, a PEG ratio of 2.52 and a beta of 0.85. The company has a 50-day simple moving average of $577.00 and a 200-day simple moving average of $517.24. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 EPS. The firm's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the business's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 over the last quarter. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.